Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | Exciting developments in ADCs for BC presented at ESMO Breast 2022

Rupert Bartsch • 5 May 2022
ESMO Breast 2022
Breast Cancer Antibodies
BEGONIA

Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, talks on the latest exciting news presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 meeting, with emphasis on developments in antibody-drug conjugates (ADCs) for both HER2-positive breast cancer and triple-negative breast cancer (TNBC). This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

More from Rupert Bartsch

2:09
The evolution of HER2 targeting in metastatic breast breast cancer
Rupert Bartsch • 7 Dec 2022
1:51
ELEANOR interim analysis: real-world study of adjuvant neratinib in HER2+/HR+ early breast cancer
Rupert Bartsch • 7 Dec 2022
0:53
ELEANOR: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancer
Rupert Bartsch • 7 Dec 2022
1:18
The advantage of ADCs for the treatment of brain metastases
Rupert Bartsch • 5 May 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals